DEG6498
/ Degron Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 18, 2026
Molecular glue degraders of the RNA binding protein HuR to treat BRAF-mutant colorectal cancer
(AACR 2026)
- "A Phase I clinical trial has been initiated to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of DEG6498 in patients with advanced solid tumors, including BRAF-mutant CRC as an expansion cohort. This trial marks a significant milestone as the first-in-human study of a HuR-targeted molecular glue degrader, offering a novel therapeutic strategy with a distinct mechanism of action to overcome the limitations of current targeted therapies for this aggressive cancer subset."
First-in-human • Colorectal Cancer • Oncology • Solid Tumor • BRAF • CRBN • IL17RB
January 31, 2026
A First in Human Phase 1 Open-Label, Multicenter, Dose Escalation and Expansion Study of DEG6498 in Patients With Solid Tumors
(ChiCTR)
- P1 | N=80 | Not yet recruiting | Sponsor: Sun Yat-sen University Cancer Center; Degron Therapeutics
New P1 trial • Hepatocellular Cancer • Solid Tumor • BRAF
December 09, 2025
A Study of DEG6498 in Participants With Solid Tumors
(clinicaltrials.gov)
- P1 | N=100 | Recruiting | Sponsor: Degron Therapeutics Co. | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Oncology • Solid Tumor • BRAF
November 25, 2025
A Study of DEG6498 in Participants With Solid Tumors
(clinicaltrials.gov)
- P1 | N=100 | Not yet recruiting | Sponsor: Degron Therapeutics Co.
First-in-human • New P1 trial • Oncology • Solid Tumor • BRAF
1 to 4
Of
4
Go to page
1